Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 1, 2017

BioPharm International

  • BioPharm International-11-01-2017
  • Volume 30
  • Issue 11

Analytical Data System Update

An updated version of Shimadzu’s LabSolutions analytical data system features an operating environment for complete data management and security in networked laboratories.

An updated version of Shimadzu’s LabSolutions analytical data system incorporates additional functions to comply with data integrity regulations, and to support development and quality inspection procedures. The software features an operating environment for complete data management and security in networked laboratories and can be used with traditional peak integration methods. Users can switch between traditional and new peak integration methods during analysis, allowing the selection of an appropriate peak integration method for the circumstance. This includes selecting a traditional method for compatibility with past data.

A peak integration algorithm in the software can quantify overlapping peaks more accurately, the company reports. The intelligent peak deconvolution analysis (i-PDeA II), which uses analyte UV spectral information obtained by the PDA detector, has been improved and can be used to show data traces for single components more accurately than with the conventional peak purity method, enabling accurate quantitative values, even for co-eluting peaks. 

Shimadzu


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.